Abstract
Background: The computational studies on 2-phenazinamines with their protein targets have been carried out to design compounds with potential anticancer activity. This strategy of designing compounds possessing selectivity over specific tyrosine kinase has been achieved through G-QSAR and molecular docking studies.
Methods: The objective of this research has been to design newer 2-phenazinamine derivatives as Bcr-Abl tyrosine kinase inhibitors by G-QSAR, molecular docking studies followed by wet lab studies along with evaluation of their anticancer potential. Computational chemistry was done by using VLife MDS 4.3 and Autodock 4.2 followed by wet lab experiments for synthesizing 2- phenazinamine derivatives. The chemical structures of ligands in 2D were drawn by employing Chemdraw 2D Ultra 8.0 and were converted into 3D. These were optimised by using semiempirical method called MOPAC. The protein structure was retrieved from RCSC protein data bank as PDB file. The binding interactions of protein and ligands were done by using PYMOL. The molecular properties of the designed compounds were predicted in silico by using Osiris property explorer. Later, we synthesized novel 13 2-phenazinamine derivatives by treating parent compound with various aldehydes in the presence of dicyclohexylcarbodiimide (DCC) and urea to afford 2-(2-chlorophenyl)-3-(phenazin-2-yl) thiazolidin-4-one and another series of derivatives synthesized with different aldehydes in the presence of p-toluylsulphonic acid, diphydropyridine and benzene sulfonyl chloride to afford benzenesulfonyl-N-(2-chlorobenzyl)-phenazin-2-amine. All the derivatives were tested for invitro anticancer activity on K562 human chronic myelogenous leukemia cell line by employing MTT assay method.
Results: The developed G-QSAR models were found to be statistically significant with respect to training (r2=0.8074), cross-validation (q2=0.6521), and external validation (pred_r2=0.5892). The best developed G-QSAR model suggested that the XlogP values of phenazinamine derivatives were found to be highly influential in determining biological activity. The standard drug was found to exhibit binding energy - 6.79 kcal/mol and the derivatives 5b and 6c exhibited binding energy of - 7.46 and - 8.51; respectively.
Conclusion: Compounds 5b, 6c were observed to possess good lipophilicity and were found to exhibit better activity than other compounds in the series, although less than standard doxorubicin. The synthesis of these 2-phenazinamine derivatives (5a-m) is reported to be obtained from 2,4- dinitrodiphenylamine by applying appropriate synthetic route. Compounds 5b and 6c showed better cytotoxic activity against K562 cancer cell line when compared to other compounds of the series, although less than standard doxorubicin.
Keywords: Anticancer activity, autodock 4.2, computer aided drug design, G-QSAR, K562, osiris property explorer, phena-zinamine
[http://dx.doi.org/10.1080/10810730600637574] [PMID: 16641080]
[http://dx.doi.org/10.1038/nrc3237] [PMID: 22437869]
[http://dx.doi.org/10.1016/S0165-6147(00)89046-X]
[http://dx.doi.org/10.1007/s10822-007-9162-7] [PMID: 18189157]
[http://dx.doi.org/10.1021/ci0504317] [PMID: 16711744]
[http://dx.doi.org/10.2174/1568026611212240007] [PMID: 23368103]
[http://dx.doi.org/10.1016/j.micres.2012.02.008] [PMID: 22494896]
[http://dx.doi.org/10.1007/s10482-004-6540-1] [PMID: 15726290]
[http://dx.doi.org/10.2174/1389557053175362] [PMID: 15777266]
[http://dx.doi.org/10.3390/md10050963] [PMID: 22822350]
[http://dx.doi.org/10.1016/j.ejmech.2013.07.017] [PMID: 23995213]
[http://dx.doi.org/10.1007/BF00128336] [PMID: 2197373]
[http://dx.doi.org/10.1007/s10822-010-9352-6] [PMID: 20401516]
[PMID: 19499576]
[http://dx.doi.org/10.1021/ci800063v] [PMID: 18642866]
[http://dx.doi.org/10.1023/B:JCAM.0000017496.76572.6f] [PMID: 15072435]
[PMID: 19085980]
[http://dx.doi.org/10.1186/1756-0500-4-445] [PMID: 22026969]
[http://dx.doi.org/10.1111/j.1747-0285.2007.00588.x] [PMID: 17986206]
[http://dx.doi.org/10.1016/0003-2697(87)90088-1] [PMID: 3619028]
[http://dx.doi.org/10.1016/S0021-9673(00)96387-8]
[http://dx.doi.org/10.1016/S0021-9673(03)00435-7] [PMID: 12877208]
[http://dx.doi.org/10.1177/875647939000600106]
[http://dx.doi.org/10.1080/10408340500526766]
[http://dx.doi.org/10.1002/ajpa.21540] [PMID: 21590752]
[http://dx.doi.org/10.1016/0165-1765(81)90026-4]
[http://dx.doi.org/10.1006/jmps.1999.1279] [PMID: 10733860]
[http://dx.doi.org/10.1016/j.cell.2011.08.046] [PMID: 22000011]
[http://dx.doi.org/10.1056/NEJM200104053441401] [PMID: 11287972]
[http://dx.doi.org/10.1016/S1470-2045(00)00149-2] [PMID: 11905636]
[http://dx.doi.org/10.1038/nm0596-561] [PMID: 8616716]
[http://dx.doi.org/10.1002/(SICI)1097-0320(19971001)29:2<97:AID-CYTO1>3.0.CO;2-J] [PMID: 9332815]